A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00429091
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
243
Enrollment
INDUSTRY
Sponsor class
Conditions
Attention-Deficit/Hyperactivity Disorder
ADHD
Interventions
DRUG:
ABT-894
DRUG:
atomoxetine
DRUG:
placebo
Sponsor
Abbott